EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome (PCOS) in Paediatric Populations
Published: Oct 01, 2013
FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, the Swiss specialty pharmaceutical company, is pleased to announce that it has been awarded funding of EUR 5.9 million by the European Commission's 7th Framework Programme. The grant supports a consortium project for the development of EX404, effervescent metformin soluble, for PCOS (Grant no. 602243) in adolescent girls. The project, titled "Metfizz", is expected to run for 42 months. EffRx will co-ordinate the high-quality, pan-European consortium consisting of Klifo (DK), Sciprom (CH), Charles Campbell Associates (2000) Ltd. (UK), Sermes (ES), Randomized Clinical Trials (RCTs) (FR), and the University of Liverpool (UK).
Help employers find you! Check out all the jobs and post your resume.